Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Subscribe To Our Newsletter & Stay Updated
